Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
20 April 2026
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
9 April 2026
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
9 April 2026
The industry’s first ALK degrader starts its first human study.
8 April 2026
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
8 April 2026
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
7 April 2026
A $3.15bn deal follows a December 2024 option agreement.
2 April 2026
The groups spend big on Terns and Arcellx.